$966 Billion is the total value of Casdin Capital, LLC's 33 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 18.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $66,281,600,000 | +30.2% | 880,000 | +162.7% | 6.86% | +43.9% |
| BLUE | Buy | BLUEBIRD BIO INC | $56,239,750,000 | +18.7% | 612,500 | +64.4% | 5.82% | +31.2% |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $31,273,721,000 | -29.4% | 3,048,121 | +1.5% | 3.24% | -21.9% |
| AGIO | Buy | AGIOS PHARMACEUTICALS INC | $30,294,000,000 | +22.7% | 935,000 | +88.9% | 3.14% | +35.7% |
| CDNA | Buy | CAREDX INC | $22,610,000,000 | +214.1% | 1,000,000 | +400.0% | 2.34% | +247.2% |
| FIXX | Buy | HOMOLOGY MEDICINES INC | $14,842,000,000 | +1.8% | 820,000 | +10.1% | 1.54% | +12.5% |
| ALEC | Buy | ALECTOR INC | $11,695,182,000 | +14.8% | 811,039 | +47.2% | 1.21% | +26.8% |
| DNLI | Buy | DENALI THERAPEUTICS INC | $9,958,000,000 | +19.9% | 650,000 | +62.5% | 1.03% | +32.7% |
| FULC | New | FULCRUM THERAPEUTICS INC | $5,606,052,000 | – | 844,285 | +100.0% | 0.58% | – |
| ORTX | Buy | ORCHARD THERAPEUTICS PLCadr | $3,682,800,000 | +163.2% | 310,000 | +210.0% | 0.38% | +190.8% |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $3,394,000,000 | – | 100,000 | +100.0% | 0.35% | – |
| TPTX | Buy | TURNING POINT THERAPEUTICS I | $2,820,000,000 | +15.5% | 75,000 | +25.0% | 0.29% | +27.5% |
| STOK | Buy | STOKE THERAPEUTICS INC | $2,793,700,000 | +12.7% | 130,000 | +52.9% | 0.29% | +24.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-01-03
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-28 |
| 4 | 2024-05-28 |
| 4 | 2024-05-22 |
| SC 13D/A | 2024-05-22 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-15 |
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.